Acurx pharmaceuticals inc ACXP.US 總覽分析
ACXP 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
價值面評分較低,若以價值投資為目標,已經有長期投資部位可能需陸續減碼
ACXP 近期報酬表現
9.83%
Acurx pharmaceuticals inc
4.57%
同產業平均
3.26%
S&P500
與 ACXP 同產業的標的表現
- TPST Tempest therapeutics inc價值 2 分趨勢 2 分波段 4 分籌碼 1 分股利 1 分查看更多
ACXP 公司資訊
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.